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ABSTRACT   Helicobacter pylori  infection is closely associated with gastric cancer, and its 
eradication is expected to prevent gastric cancer. However, gastric cancer is often detected 
discovered after eradication therapy for H. pylori  infection. We aimed to investigate the 
endoscopic and clinical features of advanced gastric cancer after H. pylori  eradication.
   We retrospectively investigated tumor location, macroscopic and histological type, 
endoscopic gastric mucosal atrophy (using the Kimura-Takemoto classification), and the interval 
between eradication and detection of gastric cancer.
   Nine patients (five males; mean age, 65.3 years [range, 44-79 years]), histologically diagnosed 
with advanced gastric cancer after successful H. pylori  eradication between April 2003 and 
December 2018, were enrolled in this study.
   In all cases, the cancer was located in the middle-to-upper portion of the stomach. With 
respect to macroscopic type, six cases were ulcerative, two were scirrhous, and one was 
polypoid. Histologically, all cancers were poorly or moderately differentiated adenocarcinomas. 
Endoscopic mucosal atrophy was mild in two cases, moderate in two cases, and severe in five 
cases. Two cases of scirrhous tumors developed from mild mucosal atrophy. Moreover, the 
tumor was detected within 36 months after H. pylori  eradication in six patients (maximum: 120 
months, mean: 38.7 months).
〈Regular Article〉
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INTRODUCTION
   The association between Helicobacter pylori 
(H. pylori) infection and development of gastric 
cancer (GC) is well established, as ascertained 
by epidemiologic studies１－３）,  experimental 
carcinogenesis in Mongolian gerbils４，５）, the 
findings of a prospective observational study６）, and 
the prevention of GC by eradication therapy７－14）. 
Uemura et al.６） reported that GC developed in 36 
(2.9%) of 1246 H. pylori-infected patients, but in 
none of the 280 uninfected patients, over a mean 
follow-up period of 7.8 years. In large randomized 
controlled trials (8, 9) and in recent meta-analyses 
and systematic reviews10－14）, the incidence of 
primary and metachronous GC significantly 
decreased following H. pylori eradication compared 
with patients not undergoing eradication.
   On the other hand, GC may occur after successful 
eradication of H. pylori. In our previous prospective 
s tudy 15）,  GC was detected af ter  successful 
eradication therapy in 20 (17 male, male:female 
ratio = 5.7:1) of 1787 patients (1.1%), and the risk 
of GC was determined as 2.2% at nine years after 
H. pylori eradication (0.24% per year). Additionally, 
our study15）, along with others16－18）, revealed that 
such metachronous GCs were primarily of the 
early, non-cardiac, intestinal type with ulceration, 
and mostly occurred in patients that had exhibited 
baseline severe atrophic gastritis of the corpus. 
Therefore, regular endoscopic surveillance is 
necessary even after successful eradication of 
H. pylori. Additionally, in our previous study15）, 
only 1  advanced GC (poorly differentiated 
adenocarcinoma) was detected 3 years after H. 
pylori eradication. To our knowledge, few cases 
of advanced GC have been discovered after H. 
pylori eradication. Although advanced GC affects 
a patient’s prognosis, the features of this particular 
class of advanced tumors is unclear. The aim of 
our study was to investigate retrospectively the 
endoscopic and clinicopathological features of 
advanced GC discovered after H. pylori eradication.
SUBJECTS AND METHODS
Patients
   This study was conducted in two hospitals from 
April 2003 through December 2018. We enrolled 
nine patients (five men, mean age 65.3 years [range 
44-79 years, median 66.0 years]) in whom GC had 
not been detected before H. pylori eradication, but 
in whom advanced GC had been histologically 
diagnosed after successful H. pylori eradication. GC 
after H. pylori eradication was defined as a gastric 
neoplasm identified approximately one year after 
eradication was confirmed to be successful.
   Seven patients (four males) attended one hospital, 
and two (one male) attended the other. All patients 
received eradication therapy for H. pylori from 
2000 through 2017. The 13C-urea breath test 
(UBiT, Otsuka Corporation, Tokyo, Japan) was 
performed for each patient to determine H. pylori 
status (confirmation of eradication) at least two 
months after completion of therapy. Moreover, 
when GC was suspected, each patient underwent 
esophagogastroduodenal examination and biopsy 
for the diagnosis of GC and a 13C-urea breath test 
   Our data demonstrated that post-eradicated advanced gastric cancers were located in 
the middle-to-upper portion of the stomach and were mainly ulcerative, poorly or moderately 
differentiated adenocarcinoma. More than half of the patients exhibited severe mucosal atrophy. 
Notably, advanced gastric cancer of the scirrhous type may develop from mild mucosal atrophy.
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for H. pylori infection.
   The study protocol was approved by our 
institution’s Ethics Committee (approval number: 
3404 and 3404-1) and has been performed in 
accordance with the ethical standards laid down 
in the Declaration of Helsinki (as revised in Brazil 
2013).
   The contents of this study are presented on the 
hospital website, where patients may opt out at any 
time.
Endoscopy
   In line with our standard procedure, target biopsy 
was performed when gastric cancer was suspected 
by endoscopy. An Olympus (GIF-H240, GIF-H260, 
or GIF-HQ290; Olympus Corporation, Tokyo, 
Japan) or FUJIFILM (EG-530N or EG-L580NW7; 
Fujifilm Holdings Corporation, Tokyo, Japan) 
videoscope was used throughout the study. Biopsy 
specimens were obtained from lesions suspected 
to be GC or another major gastric disease, such as 
gastric ulcer, and assessed histologically. Mucosal 
atrophy was evaluated during endoscopy using the 
Kimura-Takemoto classification system19）. This 
system is used to divide gastric mucosal atrophy 
into six grades (C-I, C-II, C-III, O-I, O-II, and 
O-III) based on endoscopic findings of the extent 
of the atrophic border. C-I and C-II are defined as 
mild atrophy, C-III and O-I are defined as moderate 
atrophy, and O-II and O-III are defined as severe 
atrophy.
Diagnosis of gastric cancer
   For the purposes of this study, GC was defined 
as malignant epithelial tumor cells with glandular 
differentiation, and an evident invasion of neoplastic 
epithelium into the lamina propria of the mucosa 
or beyond. Early GC was defined as invasion of 
neoplastic epithelium limited to the lamina propria 
of the mucosa, or the submucosa, and advanced GC 
was defined as invasion beyond the submucosa.
   Location, macroscopic and histological type, 
depth, and stage of tumors were defined according 
to the Japanese Classification of Gastric Carcinoma, 
15th edition20）. Location was classified as either 
U (upper: fundus-upper corpus), M (middle: 
angulus-mid corpus), or L (lower: antrum and 
pylorus). In addition, the position on the gastric 
wall was classified as either anterior, posterior, 
lesser curvature, or greater curvature. Tumor size 
was expressed as the maximum diameter of the 
resected specimen. Macroscopic type was classified 
as either type 1 (polypoid), type 2 (localized 
ulcerative), type 3 (infiltrating ulcerative), or type 
4 (diffusely infiltrating). The degree of tumor 
differentiation (histological type) was classified 
as well-differentiated tubular adenocarcinoma 
(tub1), papillary adenocarcinoma (pap), moderately 
differentiated tubular adenocarcinoma (tub2), poorly 
differentiated adenocarcinoma (por), or others, 
such as signet-ring cell carcinoma (sig). When 
a tumor consisted of more than one histological 
type, all were described regardless of the grade of 
malignancy. Depth of advanced tumor invasion was 
classified as muscularis propria (MP), subserosal 
(SS), serosal exposure (SE), or serosal invasion 
(SI). Tumor stage was classified, according to tumor 
depth, metastasis, and lymph node metastasis, as 
one of the following: stage I (A, B), II (A, B), III (A, 
B, C), or IV. The interval of survival was defined as 
days from the date of diagnosis of advanced gastric 
cancer to December 2019.
Diagnosis of H. pylori infection and eradication 
therapy
   H. pylori infection was diagnosed if positive 
results were obtained in one or more of the 
following H. pylori tests: a 13C-urea breath test, a 
serum anti-H. pylori antibody test (E-plate, Eiken 
Chemical Co., Ltd., Tokyo, Japan) (cut-off value: 
10 U/mL), a rapid urease test (Helicocheck, Otsuka 
Corporation, Tokyo, Japan) and/or a histological 
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test (Giemsa staining). All patients were informed 
of their infection status, and those with an active H. 
pylori infection received eradication therapy for one 
week if they consented to undergo the treatment. 
First-line H. pylori eradication treatment consisted 
of lansoprazole (30 mg) or vonoprazan (20 mg) with 
amoxicillin (750 mg) and clarithromycin (200 or 
400 mg), each taken twice daily for 1 week. Where 
first-line eradication treatment failed, participants 
were provided an opportunity to undergo a second-
line regimen. Second-line eradication treatment 
consisted of lansoprazole (30 mg) or vonoprazan (20 
mg) with amoxicillin (750 mg) and metronidazole 
(250 mg), each taken twice daily for 1 week.
Outcome measures
   We retrospectively reviewed the abovementioned 
clinicopathological findings of all nine patients, as 
well as the interval since eradication and the last 
endoscopy, patient age and sex, presence of distant 
metastasis, and survival outcome.
Statistical analyses
   All statistical analyses in this study were 
Table 1. Patient demographics and clinicopathological features of advanced gastric cancer after H. pylori eradication











1 64 M M(anterior) 40 2 por SE N2 CY, Liver IV Death
2 70 M M(anterior) 25 2 por > tub2 MP N0 None IB Alive (12 yrs)
3 73 M M(anterior) 35 2 tub2 > por SS N0 None IIA Alive (12 yrs)
4 79 F U(lesser curvature) 30 3 tub2 > por SS N2 None IIIA Alive (9 yrs)
5 66 M M(greater curvature) 25 1 tub2 MP N0 None IB Alive (8 yrs)
6 67 F M-U(lesser curvature) 140 4 por SE N1 None IIIC Alive (2 yrs)
7 44 F U(greater curvature) 50 2 por > sig SS N0 None IIA Alive (1 yr)
8 60 M U(anterior) 20 2 tub2 SS N2 None IIIA Alive (1 yr)
9 65 F U(greater curvature) 40 4 por > sig SE N3 CY IV Alive (1 yr)
Clinicopathological findings are provided according the Japanese Classification of Gastric Carcinoma (15th edition)20）
performed using JMP software version 13.2 (SAS 
Institute Japan Ltd., Tokyo, Japan).
RESULTS
Clinicopathological features of advanced GC after 
H. pylori eradication
   Ta b l e  1  i n d i c a t e s  d e m o g r a p h i c s  a n d 
clinicopathological characteristics of advanced 
GC among patients who underwent eradication 
treatment. All tumors were located in the middle to 
upper portions of the stomach, four were located in 
the anterior gastric wall, three were located in the 
greater curvature, and two were located in the lesser 
curvature. With respect to macroscopic type, six 
cases were ulcerative (type 2 [n = 5], type 3 [n = 1]), 
two were scirrhous (type 4), and one was polypoid 
(type 1). The histological types were poorly or 
moderately differentiated adenocarcinoma in all 
patients.
   Eight patients survived, and one died three months 
after the operation (case 1). The mean interval of 
survival for the eight patients was 5.75 years (range, 
1-12 years; standard error of the mean, 1.77 years).
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The interval and characteristics of advanced GC 
after H. pylori eradication
   Table 2 summarizes the interval and characteristics 
of post-eradication advanced GC. The tumor was 
detected within 36 months after eradication in six 
the patients (66.7%), and after more than 36 months 
in the remaining three patients (33.3%) (maximum 
interval: 120 months, mean interval: 38.7 months 
[standard error of the mean: 11.0 months]). In 
addition, two cases (cases 7 and 8) were detected 
one year after eradication treatment. In the 
remaining seven cases, the intervals between the 
penultimate endoscopic examination and diagnosis 
of GC were 2 years or more (for these seven cases, 
the maximum interval was 84 months, the mean 
interval was 39.4 months, and the standard error of 
the mean was 8.2 months).
   The endoscopic mucosal atrophy grade was mild 
Table 2. Interval and characteristics of advanced gastric cancer after H. pylori eradication
Case Endoscopic diagnosis before eradication
Year of 
eradication









1 gastric ulcer 2000 2003 36 36 O-I
2 gastric ulcer 2005 2007 24 24 O-III
3 gastric ulcer 2005 2007 24 24 O-II
4 atrophic gastritis 2000 2010 120 84 O-II
5 atrophic gastritis 2009 2011 24 24 O-II
6 atrophic gastritis 2013 2017 48 48 C-II
7 nodular gastritis 2017 2018 12 12 C-III
8 atrophic gastritis 2017 2018 12 12 O-II
9 atrophic gastritis 2014 2018 48 36 C-II
Endoscopic mucosal atrophy was classified according to the Kimura-Takemoto classification system19）.
Fig. 1. Case of advanced gastric cancer detected two years after H. pylori eradication
(a) Gastric cancer was not detected at the start of H. pylori eradication. (b) Two years after eradication, gastric cancer 
was detected in the anterior of the angulus with severe mucosal atrophy. (c) Macroscopic photo of the resected 
specimen revealed that it was a localized ulcerative tumor (type 2). (d) Pathological findings revealed that it was a 
combination of poorly and moderately differentiated adenocarcinoma (hematoxylin-eosin, 10x40)
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in two cases, moderate in two cases, and severe in 
five cases. To be noted, the two cases (cases 6 and 
9) of scirrhous-type tumors developed from mild 
atrophy of the corpus. The endoscopic diagnosis 
before eradication treatment was gastric ulcer in 
three cases, atrophic gastritis in five cases, and 
nodular gastritis in one case. None of the cases had 
a history of duodenal ulcer.
   A representative case is demonstrated in Fig. 1 
(case 2). This 70-year-old male had a gastric ulcer 
for five years before eradication therapy. No tumor 
was evident at the start of H. pylori eradication 
(Fig. 1a). Two years after successful H. pylori 
eradication, an irregular, localized ulcerative tumor 
was detected in the anterior of the lower corpus (Fig. 
1b). The degree of endoscopic mucosal atrophy was 
severe (O-III) and the atrophy was accompanied by 
xanthoma. The gastric tumor was resected via distal 
gastrectomy (Fig. 1c) and pathological findings 
revealed a combination of poorly differentiated 
adenocarcinoma and moderately differentiated 
tubular adenocarcinoma (Fig. 1d).
DISCUSSION
   In the present study, we investigated nine cases of 
advanced GC discovered after H. pylori eradication. 
We revealed that all tumors were located in the 
middle to upper portion of the stomach, the majority 
(6/9) were ulcerative, all were poorly or moderately 
differentiated adenocarcinomas, and more than half 
(5/9) exhibited severe mucosal atrophy. Notably, 
scirrhous type GC occurred in cases with only 
mild mucosal atrophy. Unfortunately, we did not 
determine the frequency of advanced tumors among 
GCs identified after H. pylori eradication in this 
study.
   Previous studies demonstrated that gastric mucosal 
atrophy15，21－26）, intestinal metaplasia15，22－25）, and 
map-like redness25，26） are potential risk factors for 
development of GC after H. pylori eradication. 
Take et al.21） demonstrated that the grade of 
gastric endoscopic mucosal atrophy was closely 
related to the development of post-eradication GC. 
Specifically, during a mean follow-up time of 3.9 
years, GC developed in 9 of 953 patients cured 
of infection and in 4 of 178 who had persistent 
infection (P = .04). Shichijo et al.22） indicated that 
patients with histologic intestinal metaplasia or 
severe endoscopic atrophy were at a higher risk 
for GC development after eradication treatment, 
compared with patients without intestinal metaplasia 
or those with no/mild mucosal atrophy. On the other 
hand, in a recent long-term follow-up study (mean 
follow-up of 7.1 years), Take et al.24） indicated that, 
in the second decade after eradication treatment, 
patients with mild-to-moderate baseline gastric 
atrophy were more likely to develop diffuse-type 
GC than intestinal-type GC. In our study, two 
cases (case 6 and 9) with scirrhous tumors also 
developed from mild atrophy of the corpus. Regular 
endoscopic surveillance (once a year) should 
therefore be continued after eradication of H. pylori, 
irrespective of the severity of gastric atrophy.
   In our study, one patient succumbed three months 
after gastrectomy (case 1). In this case, liver 
metastasis was observed at the time of discovery 
of the GC, and the cancer was stage IV. To reduce 
fatalities due to GC after H. pylori eradication, 
the disease must be detected before it becomes 
advanced. Therefore, annual, detailed endoscopy 
is required for patients who have undergone 
eradication therapy. However, in our study, annual 
endoscopic examinations were not performed in 
seven cases, and GC was discovered after an interval 
of at least 2 years after the penultimate examination. 
Reasons for irregular post-eradication endoscopies 
may be that patients are poorly informed or that a 
patient is refused examination.
   Most gastric cancer cases after eradication were 
detected in early stages, but in the current analysis, 
we focused on advanced cases. In our study, the 
primary locations of GC were the anterior wall of 
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the angulus and the greater curvature of the corpus. 
Endoscopic observation is likely to be tangential 
to the anterior and posterior wall of the angulus. 
Moreover, the gastric wall may be insufficiently 
stretched due to poor insufflation in the greater 
curvature of the corpus, which may cause the lesion 
to be missed. Therefore, careful detailed endoscopic 
observation is needed for these areas. Second, recent 
reports27，28） have demonstrated that eradication of H. 
pylori increased the risk of developing of intestinal-
type GC with submucosal invasion despite annual 
follow-up endoscopy. Finally, Menon and Trudgill29） 
revealed that 4.3 % - 9.5 % of upper gastrointestinal 
cancers are missed in endoscopic screenings 
performed in the year before diagnosis. In our 
study, two cases (case 7 and 8) were diagnosed 
one year after eradication; it is possible that these 
cases already had GC at the time of eradication, but 
that endoscopic examination yielded false negative 
results at the time.
   There were several limitations to this study. 
First, the number of patients was too small 
for generalization. In future, we will consider 
expanding the study to multiple medical centers in 
Japan and possibly to other Asian countries. Second, 
it was retrospective in nature. Third, the periods 
of follow-up were relatively short. We will also 
consider performing a similar study with a longer 
follow-up period after H. pylori eradication in future 
studies. Fourth, it is difficult to distinguish between 
previously missed lesions and new lesions. In the 
near future, we would like to prospectively evaluate 
the characteristics of advanced GC after H. pylori 
eradication in a large, multicenter study.
   In conclusion, our data suggests that nine 
advanced GCs after H. pylori eradication are 
mainly located in the middle to upper portion of 
the stomach, are predominantly ulcerative, and 
classified as poorly or moderately differentiated 
adenocarcinoma with severe mucosal atrophy. We 
also demonstrated that scirrhous-type advanced GC 
may develop from mild mucosal atrophy.
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